BioXcel Therapeutics Statistics Share Statistics BioXcel Therapeutics has 6.06M
shares outstanding. The number of shares has increased by 135.93%
in one year.
Shares Outstanding 6.06M Shares Change (YoY) 135.93% Shares Change (QoQ) 84.06% Owned by Institutions (%) 0.99% Shares Floating 5.49M Failed to Deliver (FTD) Shares 126 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 1.52M, so 10.42% of the outstanding
shares have been sold short.
Short Interest 1.52M Short % of Shares Out 10.42% Short % of Float 10.8% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.25 and the forward
PE ratio is -1.17.
BioXcel Therapeutics's PEG ratio is
0.
PE Ratio -0.25 Forward PE -1.17 PS Ratio 6.69 Forward PS 5.1 PB Ratio -0.16 P/FCF Ratio -0.21 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for BioXcel Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.68,
with a Debt / Equity ratio of -1.11.
Current Ratio 1.68 Quick Ratio 1.65 Debt / Equity -1.11 Debt / EBITDA -2.33 Debt / FCF -1.43 Interest Coverage -4.44
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $61.24K Profits Per Employee $-1.61M Employee Count 37 Asset Turnover 0.06 Inventory Turnover 3.16
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -56.64% in the
last 52 weeks. The beta is 0.21, so BioXcel Therapeutics's
price volatility has been higher than the market average.
Beta 0.21 52-Week Price Change -56.64% 50-Day Moving Average 3.12 200-Day Moving Average 3.46 Relative Strength Index (RSI) 48.02 Average Volume (20 Days) 9,465,420
Income Statement In the last 12 months, BioXcel Therapeutics had revenue of 2.27M
and earned -59.6M
in profits. Earnings per share was -23.51.
Revenue 2.27M Gross Profit 123K Operating Income -67.25M Net Income -59.6M EBITDA -44.16M EBIT -44.47M Earnings Per Share (EPS) -23.51
Full Income Statement Balance Sheet The company has 29.85M in cash and 102.95M in
debt, giving a net cash position of -73.09M.
Cash & Cash Equivalents 29.85M Total Debt 102.95M Net Cash -73.09M Retained Earnings -650.2M Total Assets 25.79M Working Capital -8.13M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -72.03M
and capital expenditures 0, giving a free cash flow of -72.03M.
Operating Cash Flow -72.03M Capital Expenditures n/a Free Cash Flow -72.03M FCF Per Share -28.41
Full Cash Flow Statement Margins Gross margin is 5.43%, with operating and profit margins of -2967.56% and -2630.14%.
Gross Margin 5.43% Operating Margin -2967.56% Pretax Margin -2630.14% Profit Margin -2630.14% EBITDA Margin -1948.85% EBIT Margin -2967.56% FCF Margin -3178.6%
Dividends & Yields BTAI does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for BTAI is $65,
which is 1615% higher than the current price. The consensus rating is "Buy".
Price Target $65 Price Target Difference 1615% Analyst Consensus Buy Analyst Count 4
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Feb 10, 2025. It was a
backward
split with a ratio of 1:16.
Last Split Date Feb 10, 2025 Split Type backward Split Ratio 1:16
Scores Altman Z-Score -42.07 Piotroski F-Score 2
